Literature DB >> 35244578

[Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19.

D Morgado-Carrasco1, J Ibaceta-Ayala2, J Piquero-Casals3.   

Abstract

Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties. It has a good safety profile, can be used in children and in pregnant and breastfeeding women, and does not suppress the immune system. Regular screening for retinopathy, one of the drug's most feared adverse effects, is necessary. Hydroxychloroquine is a widely used, essential drug in dermatology. Clinical response rates are good in lupus erythematous, where it is a first-line therapy, as well in numerous autoimmune/inflammatory diseases, including lichen planus, polymorphic light eruption, porphyria cutanea tarda, granuloma annulare, and sarcoidosis. In 2020, it was widely prescribed both to prevent and to treat COVID-19 caused by SARS-CoV-2. Its increased use led to serious supply shortages and in some cases stocks were entirely depleted. Recent meta-analyses have concluded that hydroxychloroquine is ineffective against COVID-19 and have advised against its use.
Copyright © 2022. Publicado por Elsevier España, S.L.U.

Entities:  

Keywords:  COVID-19; Dermatology; Dermatología; Desabastecimiento; Hidroxicloroquina; Hydroxychloroquine; Lichen planus; Liquen plano; Lupus eritematoso; Lupus erythematosus; Supply shortages

Year:  2022        PMID: 35244578      PMCID: PMC8893285          DOI: 10.1016/j.ad.2022.01.012

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  53 in total

1.  Childhood actinic lichen planus: successful treatment with antimalarials.

Authors:  Paloma Ramírez; Marta Feito; Elena Sendagorta; Maria González-Beato; Raul De Lucas
Journal:  Australas J Dermatol       Date:  2010-09-29       Impact factor: 2.875

2.  Hydroxychloroquine and chronic erythema nodosum.

Authors:  P Jarrett; M J Goodfield
Journal:  Br J Dermatol       Date:  1996-02       Impact factor: 9.302

3.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Authors:  Ronald B Melles; Michael F Marmor
Journal:  JAMA Ophthalmol       Date:  2014-12       Impact factor: 7.389

4.  Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

Authors:  Samya Mohammad; Megan E B Clowse; Amanda M Eudy; Lisa G Criscione-Schreiber
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-09       Impact factor: 4.794

5.  Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.

Authors:  Anagha Bangalore Kumar; Elizabeth K Blixt; Lisa A Drage; Rokea A El-Azhary; David A Wetter
Journal:  J Am Acad Dermatol       Date:  2019-01-29       Impact factor: 11.527

6.  Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring.

Authors:  G M Murphy; J L Hawk; I A Magnus
Journal:  Br J Dermatol       Date:  1987-03       Impact factor: 9.302

7.  Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial.

Authors:  D Eisen
Journal:  J Am Acad Dermatol       Date:  1993-04       Impact factor: 11.527

8.  Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.

Authors:  Ashwani K Singal; Csilla Kormos-Hallberg; Chul Lee; Vaithamanithi M Sadagoparamanujam; James J Grady; Daniel H Freeman; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-14       Impact factor: 11.382

9.  Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system.

Authors:  Charles Chiang; Deborah Sah; Bryan K Cho; Blanca E Ochoa; Vera H Price
Journal:  J Am Acad Dermatol       Date:  2010-01-12       Impact factor: 11.527

10.  Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases.

Authors:  S Lakhanpal; W W Ginsburg; C J Michet; J A Doyle; S B Moore
Journal:  Semin Arthritis Rheum       Date:  1988-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.